326 related articles for article (PubMed ID: 26268815)
1. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.
Burmester GR; Durez P; Shestakova G; Genovese MC; Schulze-Koops H; Li Y; Wang YA; Lewitzky S; Koroleva I; Berneis AA; Lee DM; Hueber W
Rheumatology (Oxford); 2016 Jan; 55(1):49-55. PubMed ID: 26268815
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Genovese MC; Durez P; Richards HB; Supronik J; Dokoupilova E; Mazurov V; Aelion JA; Lee SH; Codding CE; Kellner H; Ikawa T; Hugot S; Mpofu S
Ann Rheum Dis; 2013 Jun; 72(6):863-9. PubMed ID: 22730366
[TBL] [Abstract][Full Text] [Related]
3. Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis.
Kapitány A; Szabó Z; Lakos G; Aleksza M; Végvári A; Soós L; Karányi Z; Sipka S; Szegedi G; Szekanecz Z
Isr Med Assoc J; 2008 Jan; 10(1):32-6. PubMed ID: 18300568
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ; McInnes IB; Kirkham B; Kavanaugh A; Rahman P; van der Heijde D; Landewé R; Nash P; Pricop L; Yuan J; Richards HB; Mpofu S;
N Engl J Med; 2015 Oct; 373(14):1329-39. PubMed ID: 26422723
[TBL] [Abstract][Full Text] [Related]
5. Interaction of HLA-DRB1*09:01 and *04:05 with smoking suggests distinctive mechanisms of rheumatoid arthritis susceptibility beyond the shared epitope.
Bang SY; Lee HS; Lee KW; Bae SC
J Rheumatol; 2013 Jul; 40(7):1054-62. PubMed ID: 23637323
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study.
Tlustochowicz W; Rahman P; Seriolo B; Krammer G; Porter B; Widmer A; Richards HB
J Rheumatol; 2016 Mar; 43(3):495-503. PubMed ID: 26834211
[TBL] [Abstract][Full Text] [Related]
7. Associations of HLA-DRB1 alleles with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in northern east part of Turkey.
Uçar F; Çapkin E; Karkucak M; Yücel B; Sönmez M; Alver A; Kaklikkaya N; Tosun M; Alemdaroğlu E; Solak M
Int J Rheum Dis; 2012 Dec; 15(6):538-45. PubMed ID: 23253237
[TBL] [Abstract][Full Text] [Related]
8. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
[TBL] [Abstract][Full Text] [Related]
9. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up.
Manivel VA; Mullazehi M; Padyukov L; Westerlind H; Klareskog L; Alfredsson L; Saevarsdottir S; Rönnelid J
Ann Rheum Dis; 2017 Sep; 76(9):1529-1536. PubMed ID: 28336519
[TBL] [Abstract][Full Text] [Related]
10. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status.
Bang SY; Lee KH; Cho SK; Lee HS; Lee KW; Bae SC
Arthritis Rheum; 2010 Feb; 62(2):369-77. PubMed ID: 20112396
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
Blanco FJ; Möricke R; Dokoupilova E; Codding C; Neal J; Andersson M; Rohrer S; Richards H
Arthritis Rheumatol; 2017 Jun; 69(6):1144-1153. PubMed ID: 28217871
[TBL] [Abstract][Full Text] [Related]
12. Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity.
Schwedler C; Häupl T; Kalus U; Blanchard V; Burmester GR; Poddubnyy D; Hoppe B
Arthritis Res Ther; 2018 Mar; 20(1):44. PubMed ID: 29540200
[TBL] [Abstract][Full Text] [Related]
13. HLA-DRB1 allele association with rheumatoid arthritis susceptibility and severity in Syria.
Mourad J; Monem F
Rev Bras Reumatol; 2013 Feb; 53(1):47-56. PubMed ID: 23588515
[TBL] [Abstract][Full Text] [Related]
14. Very high levels of anti-citrullinated protein antibodies are associated with HLA-DRB1*15 non-shared epitope allele in patients with rheumatoid arthritis.
Laki J; Lundström E; Snir O; Rönnelid J; Ganji I; Catrina AI; Bengtsson C; Saevarsdottir S; Wick MC; Alfredsson L; Klareskog L; Padyukov L
Arthritis Rheum; 2012 Jul; 64(7):2078-84. PubMed ID: 22307773
[TBL] [Abstract][Full Text] [Related]
15. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies.
Jiang X; Trouw LA; van Wesemael TJ; Shi J; Bengtsson C; Källberg H; Malmström V; Israelsson L; Hreggvidsdottir H; Verduijn W; Klareskog L; Alfredsson L; Huizinga TW; Toes RE; Lundberg K; van der Woude D
Ann Rheum Dis; 2014 Oct; 73(10):1761-8. PubMed ID: 24812286
[TBL] [Abstract][Full Text] [Related]
16. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles.
Irigoyen P; Lee AT; Wener MH; Li W; Kern M; Batliwalla F; Lum RF; Massarotti E; Weisman M; Bombardier C; Remmers EF; Kastner DL; Seldin MF; Criswell LA; Gregersen PK
Arthritis Rheum; 2005 Dec; 52(12):3813-8. PubMed ID: 16320316
[TBL] [Abstract][Full Text] [Related]
17. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide.
van der Helm-van Mil AH; Verpoort KN; le Cessie S; Huizinga TW; de Vries RR; Toes RE
Arthritis Rheum; 2007 Feb; 56(2):425-32. PubMed ID: 17265477
[TBL] [Abstract][Full Text] [Related]
18. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
Genovese MC; Durez P; Richards HB; Supronik J; Dokoupilova E; Aelion JA; Lee SH; Codding CE; Kellner H; Ikawa T; Hugot S; Ligozio G; Mpofu S
J Rheumatol; 2014 Mar; 41(3):414-21. PubMed ID: 24429175
[TBL] [Abstract][Full Text] [Related]
19. Study of the frequency of HLA-DRB1 alleles in Brazilian patients with rheumatoid arthritis.
Usnayo MJ; Andrade LE; Alarcon RT; Oliveira JC; Silva GM; Bendet I; Burlingame R; Porto LC; Pinheiro Gda R
Rev Bras Reumatol; 2011; 51(5):474-83. PubMed ID: 21952999
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis.
Dokoupilová E; Aelion J; Takeuchi T; Malavolta N; Sfikakis PP; Wang Y; Rohrer S; Richards HB
Scand J Rheumatol; 2018 Jul; 47(4):276-281. PubMed ID: 29458278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
